K091636 Page 1/2

IX - 510 (K) SUMMARY OF SAFETY AND EFFECTIVENESS:

Submitted by:

JUN 22 2009

Tadeusz Wellisz, M.D.
Ceremed, Inc.
3643 Lenawee Ave.
Los Angeles, California 90016
Tel: (310) 815-2125
Fax: (310) 815-2130

Contact Person:	Tadeusz Wellisz, M.D.
Date Prepared	June 1, 2009
Common/Usual Name:	Soluble Bone Hemostasis Implant Material
Proprietary Name:	Ostene®CT, AOC™CT, Osteotene™, Ceretene™
Regulatory Class:	Unclassified
Classification Name:	Wax, Bone
Product Code:	MTJ
Predicate Device:	Ceremed, Inc. Ostene® Soluble Bone Hemostasis Implant Material (K082491)

Description of the device:

Ostene®CT is an odorless, opaque wax-like material designed to be utilized directly out of the package. It is best used immediately following removal from the package, and can be softened and increased in stickiness by warming and by additional handling and manipulation, if so desired.

Ostene®CT is comprised of a sterile mixture of water-soluble alkylene oxide copolymers, derived from ethylene oxide and propylene oxide.* Ostene®CT contains no other additives or colorants. The wax-like material is formed into sticks of various weights ranging from .5 to 5 grams each.

As a bone hemostasis agent, Ostene®CT stops bone bleeding by the creation of a physical barrier along the edges of bones that have been damaged by trauma or cut during a surgical procedure. Ostene®CT, when placed on bone under moderate pressure, plugs the vascular openings in the bone. This plug prevents further bleeding.

Ostene®CT is provided sterile by irradiation and must not be resterilized.
*A substitution has been made in a neutral excipient copolymer.

Intended use:
Ostene®CT is indicated for use as a water-soluble implant material and for use in the control of bleeding from bone surfaces.

Substantial equivalence:
The modified Ostene®CT Soluble Bone Hemostasis Implant has the same intended use and fundamental scientific technology as the legally marketed Ostene®CT Soluble Bone Hemostasis Implant.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

JUN 22 2009

Ceremed, Inc.
% Tadeusz Wellisz, M.D.
Chairman
3643 Lenawee Avenue
Los Angeles, California 90016

Re: K091636
Trade/Device Name: Ostene®CT, AOC™CT, Osteotene™, Ceretene™
Regulatory Class: Unclassified
Product Code: MTJ
Dated: June 1, 2009
Received: June 4, 2009

Dear Dr. Wellisz:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/cdrh/mdr/ for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Mark N.Melkerson
Director
Division of Surgical, Orthopedic,
and Restorative Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

VII. INDICATIONS FOR USE:

510 (k) Number (if known): K091636

Device Name: Ostene®CT, AOC™CT, Osteotene™, Ceretene™

Indications For Use:
OSTENE®CT is indicated for use as a water-soluble implant material and for use in the control of bleeding from bone surfaces.

Prescription Use____X____ OR Over-The-Counter Use _____
(Per 21 CFR 801.109) (Optional Format 1-2-96)

(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED.)

CONCURRANCE OF CDRH, OFFICE OF DEVICE EVALUATION (ODE)

David Krone for MXM
(Division Sign-Off)
Division of Surgical, Orthopedic,
and Restorative Devices

510(k) Number K091636

_____
Division Sign-Off

510(k) Number_____